  |
| ||
| Slater Tech provides seed funding for pharmaceutical company Mnemosyne is developing a research platform targeting NMDA receptor function, one of the most impactful signaling mechanisms in the brain. The company plans to develop different therapeutic treatments for a range of cognitive and emotional disorders. The company’s lead discovery program involves a novel class of molecules as therapy for schizophrenia. Current drug treatments for schizophrenia address the so-called positive or psychotic symptoms of the condition; however, they have limited efficacy in treating the chronic negative symptoms, such as withdrawal and the cognitive dysfunction that are most closely linked to poor patient outcome. NMDA receptor signaling deficiencies are a key factor underlying the full spectrum of symptoms in schizophrenia, particularly the cognitive dysfunction. Mnemosyne’s strategy looks to correct this deficiency, significantly improving upon available therapies for schizophrenia to better treat the significant unmet medical needs of this patient group. Mnemosyne is in the process of assembling a world-class advisory board of neuroscientists and psychiatrists affiliated with leading research institutions in the field of NMDA receptor function and neuropsychiatric disease. Joining this group is Peter Snyder, PhD, professor of neurology at the Warren Alpert Medical School of Brown University and vice-president for research at the Lifespan health system and its partner hospitals in Providence. |
Bill's Bloge-Newsletters Recent FavoritesSurvey |
